Browsing publications by Dr Julie Irving

Newcastle AuthorsTitleYearFull text
Dr Sarah Fordham
Mike Cole
Dr Julie Irving
Dr James Allan
Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia2015
Dr Julie Irving
Elizabeth Matheson
Helen Blair
Marian Case
Isabella Swidenbank
et al.
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420-34302015
Dr Sarah Fordham
Mike Cole
Dr Julie Irving
Dr James Allan
Cytarabine leaves a mutational fingerprint in relapsing leukemia2014
Dr Julie Irving
Elizabeth Matheson
Dr Helen Blair
Marian Case
Isabella Swidenbank
et al.
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition2014
Dr Klaus Rehe
Kerrie Wilson
Dr Simon Bomken
Dr Daniel Williamson
Dr Julie Irving
et al.
Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations2013
Professor Graham Jackson
Dr Julie Irving
Dr James Allan
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk2013
Dr Julie Irving
Dr James Allan
Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype2013
Dr Lindsay Nicholson
Elizabeth Matheson
Lynne Minto
Marian Case
Maryna Sanichar
et al.
Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia2012
Dr Julie Irving
Dr James Allan
Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia2012
Dr Julie Irving
Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data2012
12345678910